Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8436124 | 0.81 | KCNN4 (0.54) | KCNN4ALDH1A1P2RX7TSHRNOTUM | |
| SCHEMBL13322089 | 0.81 | ALDH1A1 (0.66) | KCNN4ALDH1A1P2RX7TSHRSMN1; SMN2 | |
| SCHEMBL5546019 | 0.79 | KCNN4 (0.49) | KCNN4ALDH1A1TSHRNOTUMSMN1; SMN2 | |
| SCHEMBL10231735 | 0.79 | L3MBTL1 (0.49) | KCNN4ALDH1A1TSHRNOTUML3MBTL1 | |
| SCHEMBL5545479 | 0.78 | KCNN4 (0.60) | KCNN4 | |
| SCHEMBL10577284 | 0.78 | ALDH1A1 (0.45) | KCNN4ALDH1A1TSHRNOTUML3MBTL1 | |
| SCHEMBL28898079 | 0.78 | ALDH1A1 (0.51) | KCNN4ALDH1A1P2RX7TSHRNOTUM | |
| SCHEMBL27610654 | 0.78 | KCNN4 (0.51) | KCNN4ALDH1A1P2RX7TSHRNOTUM | |
| SCHEMBL3295145 | 0.78 | KCNN4 (0.51) | KCNN4ALDH1A1P2RX7TSHRNOTUM | |
| SCHEMBL2657681 | 0.77 | L3MBTL1 (0.48) | KCNN4ALDH1A1TSHRNOTUML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KCNN4 3997/4885ALDH1A1 355/4885P2RX7 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.